DelveInsight’s “Graves’ Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Explore Graves’ Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/graves-disease-market
Key Takeaways from the Graves’ Disease Market Report
- In December 2025, Sanofi announced a Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves’ disease, with and without Graves’ orbitopathy, aged 18 years or older.
- In December 2025, Immunovant Sciences GmbH conducted a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
- Among the 7MM, the US accounted for approximately 48%, EU4 and the UK for 46%, and Japan for 6% of the total prevalent cases of Graves’ disease in 2023.
- As per the DelveInsight estimates, it has been found that there were approximately 3,720,200 diagnosed prevalent cases of Graves’ disease in the 7MM in 2023.
- In 2023, the manifestation of Graves’ disease in the US showed that Graves’ Ophthalmopathy captured the highest number of cases, i.e., approximately 584,400 cases.
- In 2023, the gender-specific diagnosed prevalent cases of Graves’ disease in Japan were approximately 80,450 cases for males and approximately 321,800 cases for females.
- The leading Graves’ Disease Companies such as Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
- Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
Discover which therapies are expected to grab the Graves’ Disease Market Share @ Graves’ Disease Treatment Market
Graves’ Disease Overview
Graves’ disease is an autoimmune disorder and the most common cause of hyperthyroidism, characterized by the overproduction of thyroid hormones due to the presence of thyroid-stimulating immunoglobulins that activate the thyroid-stimulating hormone (TSH) receptor. This excessive hormone secretion leads to a hypermetabolic state, resulting in symptoms such as weight loss, heat intolerance, palpitations, anxiety, tremors, and fatigue, along with a diffusely enlarged thyroid gland (goiter).
Graves’ Disease Epidemiology Insights
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
• Graves’ Disease Gender-specific Cases
• Total Graves’ Disease Prevalent Cases
• Graves’ Disease Age Group-specific Cases
• Total Graves’ Disease Treated Cases
Download the report to understand which factors are driving Graves’ Disease epidemiology trends @ Graves’ Disease Prevalence
Graves’ Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves’ Disease market or expected to get launched during the study period. The analysis covers Graves’ Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Graves’ Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Graves’ Disease Therapies and Companies
• Sling Therapeutics, Inc.: linsitinib
• Immunovant Sciences GmbH: Batoclimab
• Amgen: Teprotumumab
• Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg
• Hoffmann-La Roche: Satralizumab
Graves’ Disease Market Outlook
There are three main treatments for Graves’ disease: ATD medications, thyroidectomy, and radioactive iodine therapy. ATD medications prevent the biosynthesis of the thyroid hormone by blocking iodide, the salted or reduced form of iodine, from interacting with thyroglobulin, thus diminishing the amount of hormone produced. Methimazole is the most widely used ATD medication, with a long half-life and low side effects. Another is carbimazole has been approved in European countries but is not approved in the United States. It is an inactive drug that is metabolized in the blood into the active methimazole thus it is less potent. And the last is propylthiouracil, which is the least potent of the available antithyroid medications. Approved in the United States and Europe, propylthiouracil is the initial treatment choice during the first trimester of pregnancy because of the low placental transfer. Propylthiouracil was, for many years, the first-choice ATD in both the USA and South America. But now the American Thyroid Association (ATA) recommends Methimazole over Propylthiouracil. Methimazole is used in most European countries and Japan, whereas carbimazole is mainly used in the UK.
Marketed Graves’ disease Drugs
• TEPEZZA (Teprotumumab-Trbw): Amgen (Horizon Therapeutics)
Teprotumumab, an insulin-like Growth Factor-1 receptor (IGF-1R) inhibitor, is a fully human IgG1 monoclonal antibody produced in Chinese hamster (CHO-DG44) cells with a molecular weight of approximately 148 KD. In January 2020, the US FDA approved TEPEZZA for the treatment of TED after an accelerated Priority Review. And recently, in September 2024, the drug was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of active Graves’ orbitopathy. Additionally, in April 2024, Amgen announced its plans to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) in the near future. TEPEZZA is currently under investigation in Phase III clinical trials for patients with moderate-to-severe active Graves’ orbitopathy as well as those with chronic TED characterized by a low Clinical Activity Score (CAS). Additionally, Amgen is exploring its potential for subcutaneous administration.
Get In-Depth Knowledge on Acute on Graves’ disease Market Trends and Forecasts with DelveInsight @ Graves’ disease Market Drivers and Barriers
Emerging Graves’ disease Drugs
• IMVT-1401 (batoclimab, RVT-1401): Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences
Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal FcRn. In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection. Currently, batoclimab is being developed as a low-volume SC injection for the treatment of a variety of IgG-mediated autoimmune disorders, including myasthenia gravis, TED, chronic inflammatory demyelinating polyneuropathy, and Graves’ disease. The drug is currently in Phase III developmental stage. Recently, in September 2024, Immunovant received Investigational New Drug (IND) clearance from the US FDA for IMVT-1402 in Graves’ disease patients who remain hyperthyroid despite treatment with antithyroid drugs. Furthermore, Immunovant plans to initiate clinical trials of IMVT-1402 in a total of ten indications by March 2026.
• VRDN-001 (veligrotug): Viridian Therapeutics
Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting Insulin-like Growth Factor-1 Receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves’ ophthalmopathy. In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves’ Ophthalmopathy therapy. Currently, the drug is currently being evaluated in various Phase III trials for the treatment of Graves’ ophthalmopathy. According to a corporate presentation published in November 2024, the potential PDUFA date and launch of veligrotug are expected in 2H 2026.
Scope of the Graves’ Disease Market Report
• Coverage: 7MM
• Study Period: 2020-2034
• Graves’ Disease Companies- Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
• Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
• Graves’ Disease Therapeutic Assessment: Graves’ Disease current marketed and Graves’ Disease emerging therapies
• Graves’ Disease Market Dynamics: Graves’ Disease market drivers and Graves’ Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement
Discover more about Graves’ Disease Drugs in development @ Graves’ Disease Ongoing Clinical Trials
Table of Contents
1. Graves’ Disease Market Report Introduction
2. Executive Summary for Graves’ Disease
3. SWOT analysis of Graves’ Disease
4. Graves’ Disease Patient Share (%) Overview at a Glance
5. Graves’ Disease Market Overview at a Glance
6. Graves’ Disease Disease Background and Overview
7. Graves’ Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graves’ Disease
9. Graves’ Disease Current Treatment and Medical Practices
10. Graves’ Disease Unmet Needs
11. Graves’ Disease Emerging Therapies
12. Graves’ Disease Market Outlook
13. Country-Wise Graves’ Disease Market Analysis (2020-2034)
14. Graves’ Disease Market Access and Reimbursement of Therapies
15. Graves’ Disease Market Drivers
16. Graves’ Disease Market Barriers
17. Graves’ Disease Appendix
18. Graves’ Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/